Literature DB >> 15796209

Cell cycle and apoptosis deregulation in classical Hodgkin lymphomas.

Maria Bai1, Alexandra Papoudou-Bai, Panagiotis Kitsoulis, Nikolaos Horianopoulos, Sevasti Kamina, Niki John Agnantis, Panagiotis Kanavaros.   

Abstract

Classical Hodgkin lymphomas (cHL) have now been recognized as B-cell lymphomas with some exceptional cases of T-cell origin. In recent years, there has been accumulating evidence that Hodgkin and Reed-Sternberg (H/RS) cells, the presumed neoplastic-cell population in cHL, are characterized by a profound disturbance of the cell cycle and apoptosis regulation. The constitutive activation of the nuclear factor (NF)-kappaB pathway, which is considered to be involved in the proliferation and survival of H/RS cells. Moreover, substantial evidence that H/RS cells have defective cell cycle and apoptosis regulation has been provided by studies showing that these cells are characterized, in a large proportion of cases, by alterations of the p53, Rb and p27 tumor suppressor pathways, overexpression of cyclins involved in the G1/S and G2/M transition such as cyclins E, D2, D3, A and B1, overexpression of cyclin-dependent kinases such as CDK1, 2 and 6 and overexpression of anti-apoptotic proteins such as c-FLIP, bcl-xl, c-IAP2, X-linked I4P and survivin. Recent studies suggest that interleukin 13 (IL-13) is an important growth and survival factor in H/RS cells. Furthermore, the Epstein-Barr Virus (EBV), which is present in H/RS cells in about 30-50% of cHL, has been shown to affect the cell cycle and apoptosis regulation in cHL. The present review summarizes data with respect to the cell cycle and apoptosis deregulation in cHL.

Entities:  

Mesh:

Year:  2005        PMID: 15796209

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  11 in total

1.  Epstein-Barr virus infection is inversely correlated with the expression of retinoblastoma protein in Reed-Sternberg cells in classic Hodgkin lymphoma.

Authors:  Suhail Al-Salam; Aktham Awwad; Mouied Alashari
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

2.  Epstein-Barr virus infection correlates with the expression of COX-2, p16(INK4A) and p53 in classic Hodgkin lymphoma.

Authors:  Suhail Al-Salam; Aktham Awwad; Manjusha Sudhadevi; Sayel Daoud; Nico J D Nagelkerke; Antonio Castella; S M Chong; Mouied Alashari
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

3.  Local cell proliferation in rheumatoid synovial tissue: analysis by cyclin expression.

Authors:  Chikako Takahashi Tohyama; Mitsunori Yamakawa; Akira Murasawa; Kiyoshi Nakazono; Hajime Ishikawa
Journal:  Clin Rheumatol       Date:  2006-03-02       Impact factor: 2.980

Review 4.  Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.

Authors:  Luis de la Cruz-Merino; Marylène Lejeune; Esteban Nogales Fernández; Fernando Henao Carrasco; Ana Grueso López; Ana Illescas Vacas; Mariano Provencio Pulla; Cristina Callau; Tomás Álvaro
Journal:  Clin Dev Immunol       Date:  2012-08-15

5.  Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.

Authors:  Ezogelin Oflazoglu; Kim M Kissler; Eric L Sievers; Iqbal S Grewal; Hans-Peter Gerber
Journal:  Br J Haematol       Date:  2008-05-08       Impact factor: 6.998

Review 6.  Hodgkin's Lymphoma in Older Patients: an Orphan Disease?

Authors:  Antoine Thyss; Esma Saada; Lauris Gastaud; Frédéric Peyrade; Daniel Re
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-07-01       Impact factor: 2.576

Review 7.  The baculoviruses occlusion-derived virus: virion structure and function.

Authors:  Jeffery Slack; Basil M Arif
Journal:  Adv Virus Res       Date:  2007       Impact factor: 9.937

8.  Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells.

Authors:  Mareike Roscher; Inis Hormann; Oliver Leib; Sebastian Marx; Josue Moreno; Erich Miltner; Claudia Friesen
Journal:  Oncotarget       Date:  2013-02

9.  Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma.

Authors:  Kung-Chao Chang; Wei-Chao Chang; Yao Chang; Liang-Yi Hung; Chien-Hsien Lai; Yu-Min Yeh; Yu-Wei Chou; Chung-Hsuan Chen
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

Review 10.  Abnormal microRNA expression in the course of hematological malignancies.

Authors:  Agnieszka Szymczyk; Arkadiusz Macheta; Monika Podhorecka
Journal:  Cancer Manag Res       Date:  2018-10-08       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.